Navigation Links
Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain
Date:7/18/2012

ressing acute and chronic pain, is on the rise.

According to recent research the global pain management market is to reach US$60 Billion by 2015[1].

As part of a restructuring of Convergence in 2011, CNV2197944 was subsequently transferred into Calchan Ltd. Calchan Ltd is developing its own portfolio of Calcium ion channel modulators and has contracted Convergence to undertake certain development activities with CNV2197944 on its behalf.

References:

  1. Global Industry Analysts Inc. 2010, "Pain Management: A Global Strategic Business Report".

http://www.strategyr.com/Pain_Management_Market_Report.asp

About Convergence Pharmaceuticals

Convergence Pharmaceuticals is an independent biotechnology company focused on the development of novel analgesics with potentially commercially attractive efficacy, responder-rate and side effect profiles. The Company, led by CEO Clive Dix, was formed in October 2010 following the acquisition of certain neuroscience clinical assets from GlaxoSmithKline ("GSK"). The Company  has a pipeline of differentiated clinical-stage compounds targeting the points of convergence in chronic pain signalling through modulation of specific ion-channels.

Convergence Pharmaceuticals is well funded and raised US$35.4 million in Series A financing from a syndicate of leading European and US financial institutions. For more information please go to the Company's website at http://www.convergencepharma.com.

For more information about Convergence Pharmaceuticals, please contact:

Convergence Pharmaceuticals
Dr Clive Dix, Chief Executive Officer
Dr Simon Tate, Chief Scientific Officer
T: +44(0)1223-755-501
E: info@convergencepharma.c
'/>"/>

SOURCE Convergence Pharmaceuticals Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. The Convergence of Art, Science and Beer
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
4. Keryx Biopharmaceuticals to Present at The 7th Annual JMP Securities Healthcare Conference
5. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
6. Access Pharmaceuticals to Report New MuGard Clinical Trial Data This Week at the MASCC/ISOO Symposium in New York City
7. Keryx Biopharmaceuticals Announces Live Webcast of Upcoming Analyst Day
8. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
9. Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
10. Questcor Pharmaceuticals Expands Repurchase Program
11. Eutropics Pharmaceuticals Receives U.S. Patent for Novel Diagnostic Method
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... December 17, 2014 Audacity, a leading ... and member of the Huntsworth Health Group, is proud ... executive team. In her role, Gonzales will serve as ... are incredibly honored to welcome a talent of Jamie’s ... CEO, Gaëtan Fraikin. “She is a proven healthcare innovation ...
(Date:12/17/2014)... , Dec. 17, 2014 CASI Pharmaceuticals, ... dedicated to the acquisition, development and commercialization of innovative ... the global market with a primary commercial focus on ... has been granted a Type C meeting with the ... meeting will be held in February 2015.  During this ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 METTLER ... inline PVM tool, ParticleView V19 with PVM ... situ probe-based particle vision and measurement tool continuously ... process conditions. ParticleView V19 then automatically prepares a ... tracking particle size and concentration changes. This compelling ...
(Date:12/15/2014)... NEW YORK , Dec. 15, 2014  GlassesOff ... Yuval Bar-Gil as an independent director of ... was founder of AeroScout and served as its CEO ... Decker in 2012, a $240 million transaction. Recognized as ... under Mr. Bar-Gil,s leadership, AeroScout provided Wi-Fi -based RFID ...
Breaking Biology Technology:Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3
... Sept. 25 Telik, Inc.,(Nasdaq: TELK ) today ... Nasdaq Stock Market, or Nasdaq, a deficiency notice letter ... bid price of Telik,s,common stock has closed below the ... Nasdaq Global Market under Marketplace Rule,4450(a)(5). In accordance with ...
... ... in FUNCTIONAL FOOD market-- LAVAL, QC, Sept. 25 ... reported today,that it entered a worldwide alliance with Marine Life ... for the distribution,of dietary supplements and functional food products in ...
... successful progress,of several vaccine programmes run by AFFiRiS GmbH ... the company. It has set up two new funds ... investors in Germany and Austria the,opportunity to invest in ... step for two reasons. First, to ensure the early,coverage ...
Cached Biology Technology:Telik Announces Receipt of Nasdaq Notice 2Neptune Technologies and Marine Life Sciences enter worldwide distribution alliance with Weider Global Nutrition 2Neptune Technologies and Marine Life Sciences enter worldwide distribution alliance with Weider Global Nutrition 3Neptune Technologies and Marine Life Sciences enter worldwide distribution alliance with Weider Global Nutrition 4AFFiRiS - MIG-Fonds Increases Investment by Euro 3 Million 2AFFiRiS - MIG-Fonds Increases Investment by Euro 3 Million 3
(Date:12/4/2014)... BEACH GARDENS, Fla. , Dec. 3, 2014 ... management solutions, today announced that its DigitalPersona ® ... 4500 fingerprint readers have been deployed throughout First ... , South Carolina ... headquartered in Southern Pines, North Carolina ...
(Date:11/21/2014)... Calif. , Nov. 20, 2014 Strict ... driver efficiency are piloting the North American and European ... of accidents growing, gesture recognition systems that are intuitive ... a mark in the industry. New ... Automotive Gesture Recognition Market in Europe ...
(Date:11/18/2014)... -- The Parenteral Drug Association (PDA) today confirmed that seven ... at least seven more will participate in the upcoming 2014 ... in Washington D.C. , Dec. 2-4. ... from the regulatory agencies in the United States ... effort to help advance the use of metrics in the ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... has been restricted in the United States since 1978, ... major countries from three continents there is still widespread ... sell consumer paints that contain dangerous levels of lead. ... and his team have found that approximately 73 percent ...
... Woods Hole, Mass., August 4, 2009 Plankton Power ... Cape Cod announced today the establishment of a ... to produce renewable biofuels from algae. Under the ... Guard, Woods Hole Oceanographic Institution (WHOI), Marine Biological ...
... the developing world is the key to ensuring food ... of the Global Form on Agricultural Research (GFAR), writing ... last week. With nearly a billion people suffering ... concern, despite being a key goal of the UN ...
Cached Biology News:Lead-based consumer paint remains a global public health threat 2Lead-based consumer paint remains a global public health threat 3Plankton Power and RTDC announce proposed algae-to-biofuels pilot facility on Cape Cod 2Plankton Power and RTDC announce proposed algae-to-biofuels pilot facility on Cape Cod 3
... sheer in-house demand is causing shortages in ... antibody. This can cause unwanted distractions, problems ... Receive royalties for your hard work and ... us build it up,and market it internationally. ...
... EKMax™ is a recombinant preparation of ... EKMax™ Enterokinase is expressed and isolated from ... highly purified enzyme preparation (2). It recognizes ... bond after the lysine residue. The enzyme ...
... causing shortages in your laboratory or fellow ... unwanted distractions, problems and delays. ... hard work and endeavour! Bring us your ... market it internationally. We work under ISO ...
... Neuromedin U-23 (rat) - Diluted Antiserum for ... Neuromedin U-23 (rat) Immunology Products, Host: ... For our corresponding peptide and ... please see Neuromedin U-23 (rat) (H-9295) and ...
Biology Products: